42nd Annual Miami Breast Cancer Conference® - Abstracts
TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study
ByAditya Bardia, MD, MPH,Virginia Kaklamani, MD, DSc,Joyce A. O’Shaughnessy,Peter Schmid, MD,J. Thaddeus Beck,,Michelino De Laurentiis,Guiseppe Curigliano,Hope S. Rugo, MD,Carlos Barcenas,William J. Gradishar, MD,Michail Ignatiadis,David Cameron,Giulia Tonini,Simona Scartoni,Jennifer Crozier,Leo Viana Nicacio,Tomer Wasserman,Sara M. Tolaney, MD, MPH
30 Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2– Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial
ByAarti Chawla,Komal Jhaveri,Patrick Neven, MD, PhD,Monica Lis Casalnuovo,Sung-Bae Kim,Eriko Tokunaga,Philippe Aftimos,Cristina Saura,Joyce A. O’Shaughnessy,Nadia Harbeck, MD, PhD,Lisa A. Carey, MD,Guiseppe Curigliano,Antonio Llombart-Cussac,Elgene Lim, MBBS, FRACP, PhD,María de la Luz García Tinoco,Joohyuk Sohn,Andre Mattar,Qingyuan Zhang,Chiun-Sheng Huang,Chih-Chiang Hung,Jorge Luis Martinez Rodriguez,Manuel Ruiz Borrego
Advertisement
Advertisement
Trending on CancerNetwork
1
177Lu-PSMA-I&T/223Ra Display Safety and Feasibility in Metastatic CRPC
2
H.R. 2541: Examining Its Legislative Impact on Radiopharmaceutical Practice
3
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
4
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
5
